TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Complement activation
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement of cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Coronary artery disease diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with serum and synovial fluid biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posterior condylar offset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PTSD Checklist for the DSM-5 (PCL-5)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dimensions of Anger Reactions (DAR)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Beck Depression Inventory (BDI-2)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: number of amplification with the NGS technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of caffeine in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of tolbutamide in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic clearance of midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With an Emergency Department (ED) Visit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to Well-established Granulation Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health utilities for SF-6Dv2
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Nocturnal Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Depression status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety and tolerability of medications
Endpoint domain: Adverse events/effects
Primary endpoint: Time to First Re-treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to Composite of Heart failure hospitalizations and/or Cardiovascular mortality
Endpoint domain: Mortality/survival
Primary endpoint: Changes to K-SADS Mania Rating Scale (KMRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose Limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Absence of nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in percent of the initial area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in seated diastolic blood pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Durable Disease Control Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Roland Morris Disability Questionnaire (RMDQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Social Interaction and Communication SRS-II Score
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Function in Daily Activities, Mobility, Social and Cognitive, and Responsibility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in ferric iron levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Improvement in patient ETD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in Cardiac index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Best Overall Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of romidepsin
Endpoint domain: Adverse events/effects
Primary endpoint: Dose-limiting toxicity of romidepsin
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic (PK) profile of romidepsin
Endpoint domain: Physiological/clinical
Primary endpoint: Proportion of subjects experiencing a major adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Assessment of responses
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Medication Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of Risky Drinkers Measured by AUDIT-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients Attending to Specialized Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Death From All Causes
Endpoint domain: Mortality/survival
Primary endpoint: Number of Patients Who Underwent Lung Transplantation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Blood oxygenation level dependent (BOLD) response to pressure stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood oxygenation level dependent (BOLD) response to painful contact heat stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of complete healing of target ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Quadriceps Muscle Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Puncture accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a 4-Fold Rise or Greater in Serum Anti-norovirus Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After First Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site After Second Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Solicited Systemic Adverse Events (AEs) After First Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Solicited Systemic Adverse Events (AEs) After Second Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Dose-Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Complete Response (CR) at End of Induction (EOI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mindfulness score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: EQ score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: MASS score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Changes in adipocyte structure and function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Characteristic electrophysiologic curve for aganglionated bowel
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Relative abundance of Bifidobacterium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Depression Symptom Severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of Change in Chair Rise Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Change in Inflammatory Index Score (IIS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paraspinal Muscle Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Visual Analog Scale Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: circulatory assistance or emergency transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: All-Cause Mortality or Disabling Stroke Rate
Endpoint domain: Mortality/survival
Primary endpoint: Device Success Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scintigraphic pattern of peripheral lung thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Pulmonary microvascular injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lung Clearance Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: progression from microalbuminuria to macroalbuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Relative bioavailability based on AUC0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative bioavailability based on AUC0-inf
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative bioavailability based on Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Haemoglobin (Hb) Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Respiratory Event Index (REI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Exhaled Carbon Monoxide Confirmed Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with normal IGF-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change in hepatic lipid content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of participants with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Total sprint time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to recurrence of macular edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Reliability of the Polish version of the AIMS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Real-world progression-free survival (rwPFS)
Endpoint domain: Mortality/survival
Primary endpoint: Clinical Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Severe Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of bolus doses required to achieve a comfort score of 17 ≤ 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug dose required to maintain a target comfort score of 17 ≤ 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline SPADI questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Annual Rate of Change in Right Common Carotid Artery Intima-media Thickness (CIMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Brachial Artery (BA) Flow Mediated Dilation (FMD) From Study Entry to Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Cardiac Ischemia Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Swelling of Mucous Membranes
Endpoint domain: Adverse events/effects
Primary endpoint: UPSIT Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Whole Mouth Lobene Modified Gingival Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet and monocyte function/activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to train of-four ratio of 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characterization of CAV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in blood glucose measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pain Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thickness of the paraspinal muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: patient-oriented composite outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Difference in daytime ABPM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Steady state plasma GSK1349572 concentration at the end of the dosing interval (Cτ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the time-concentration curve over the dosing interval (AUC(0-τ))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC for a 24-hour interval (AUC(0-24))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Clean Urine Samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in HIV-1 Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean combined daily symptoms-and-medications-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Women With Placement of LARC
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Client Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 28-day all-cause mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: Multiple Sclerosis Self-Efficacy Scale (MSSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain on Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Resolution of Anterior Chamber (AC) Cells at Day 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Complete Resolution of Ocular Pain at Day 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in the Medication Satisfaction Questionnaire (MSQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants with Treatment Emergent Treatment-Related Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Adverse Events by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of non-fatal myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Baseline Ocular Condition post-operatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Ocular Complications post-operation
Endpoint domain: Adverse events/effects
Primary endpoint: accuracy of postoperative condylar position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protective Humoral Immune Response at 1 Month Post First Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Protective Humoral Immune Response 12 Months Post First Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of subjects reporting local reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects reporting systemic events
Endpoint domain: Adverse events/effects
Primary endpoint: change in total antioxidant capacity (TAC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in malonaldehyde (MDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in nitric oxide (NO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acne Severity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Autism Parenting Stress Index
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subjective Units of Parenting Stress Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Occurrence of ovarian, fallopian tube, and peritoneal carcinoma
Endpoint domain: Mortality/survival
Primary endpoint: Number of Subjects With Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: First Event of Cardiovascular Death
Endpoint domain: Mortality/survival
Primary endpoint: Resuscitated Cardiac Arrest
Endpoint domain: Mortality/survival
Primary endpoint: Acute Myocardial Infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Urgent Hospitalization for Angina Requiring Coronary Revascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Significant Pain Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regional cerebral blood flow (rCBF) changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants with major cardiac events
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of participants using tobacco dependence treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Response Rate of Pembrolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in best corrected visual acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Absolute Total Blood Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Anti Influenza HAI Antibody Geometric Mean Titers (GMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cognitive performance as indicated by total MoCA scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percent of Participants Experiencing Death
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Event Requiring Surgical Intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of block success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: episode of gastric regurgitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percent of infants with peanut allergy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dose limiting toxicity of RG7388
Endpoint domain: Adverse events/effects
Primary endpoint: Dose limiting toxicity of combination of RG7388 and Pegasys
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive performance measured by ADCS-PACC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Platelet Activity (MPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent Change in Platelet Activity (LTA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion of participants with plasma viral load <50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: death of breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Extent of lung involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Abstinence Rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of improvement in symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of symptom relief
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pulmonary vascular resistance (PVR) at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain related disability and interference scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in pain coping
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in headache intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in headache frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of BAY1830839 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of BAY1830839 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in frequency of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in severity of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Quality of Life on SF36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: genotype distribution of APOC3 polymorphisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes